Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Capital expenditure | -789 | -579 | -769 | -598 | -556 |
| Investing cash flow | -1,053 | -243 | -1,631 | -525 | -1,212 |
| Financing cash flow | -241 | 1,106 | 603 | -2.1 | -98.9 |
| Dividends paid | -55.9 | -47.0 | -46.0 | -45.9 | -40.7 |
| Debt issued | 525 | 319 | 1,541 | 302 | 148 |
| Debt repaid | -617 | -302 | -884 | -216 | -139 |
| Effect of exchange rates | -15.9 | -23.0 | -19.5 | 6.4 | 8.8 |
| Net change in cash | -814 | 1,467 | -244 | 28.1 | -458 |
| Free cash flow | -309 | 25.3 | 16.4 | -43.0 | 297 |